logo

CYBN

Cybin
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
ample liquidity
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About CYBN

Cybin Inc.

A biopharmaceutical company that developing psychedelic therapeutics for psychiatric disorders

Pharmaceutical
Invalid Date
08/05/2021
American Stock Exchange
50
03-31
Common stock
100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9
--
Cybin Inc., was founded in 2019 in Ontario, Canada. The company operates in Canada, the United States, the United Kingdom and Ireland. The company focuses on developing psychedelics into therapies by designing patented drug discovery platforms, innovative drug delivery systems, novel formulation methods and treatment options for mental health disorders.

Company Financials

EPS

CYBN has released its 2025 Q1 earnings. EPS was reported at -0.01, versus the expected -0.03, beating expectations. The chart below visualizes how CYBN has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime